Zenlabs Ethica [ZENLABS] vs Entero Healthcare [ENTERO] Detailed Stock Comparison
Zenlabs Ethica
BSE
Loading...
Entero Healthcare
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Zenlabs Ethica wins in 6 metrics, Entero Healthcare wins in 11 metrics, with 0 ties. Entero Healthcare appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Zenlabs Ethica | Entero Healthcare | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 78.02 | 54.82 | Entero Healthcare |
| Price-to-Book Ratio | 1.99 | 3.01 | Zenlabs Ethica |
| Debt-to-Equity Ratio | 121.85 | 21.76 | Entero Healthcare |
| EV/EBITDA | 12.31 | 29.36 | Zenlabs Ethica |
| Profit Margin (TTM) | 0.52% | 1.90% | Entero Healthcare |
| Operating Margin (TTM) | 2.62% | 2.94% | Entero Healthcare |
| EBITDA Margin (TTM) | 2.62% | 2.94% | Entero Healthcare |
| Return on Equity | 2.62% | 5.36% | Entero Healthcare |
| Return on Assets (TTM) | 2.02% | 3.51% | Entero Healthcare |
| Free Cash Flow (TTM) | $38.14M | $-881.78M | Zenlabs Ethica |
| 1-Year Return | -19.26% | 4.72% | Entero Healthcare |
| Price-to-Sales Ratio (TTM) | 0.42 | 0.96 | Zenlabs Ethica |
| Enterprise Value | $316.31M | $57.20B | Entero Healthcare |
| EV/Revenue Ratio | 0.62 | 1.06 | Zenlabs Ethica |
| Gross Profit Margin (TTM) | 32.99% | 9.77% | Zenlabs Ethica |
| Revenue per Share (TTM) | $78 | $1,242 | Entero Healthcare |
| Earnings per Share (Diluted) | $0.41 | $21.78 | Entero Healthcare |
| Beta (Stock Volatility) | -0.77 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Zenlabs Ethica vs Entero Healthcare Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Zenlabs Ethica | -0.91% | -4.05% | -4.79% | 0.60% | -8.96% | -20.06% |
| Entero Healthcare | -8.05% | -1.13% | 5.00% | -4.26% | -7.68% | -10.23% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Zenlabs Ethica | -19.26% | -27.87% | 35.55% | 344.92% | 46.07% | 518.76% |
| Entero Healthcare | 4.72% | 12.11% | 12.11% | 12.11% | 12.11% | 12.11% |
Performance & Financial Health Analysis: Zenlabs Ethica vs Entero Healthcare
| Metric | ZENLABS | ENTERO |
|---|---|---|
| Market Information | ||
| Market Cap | ₹214.64M | ₹51.95B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 1,780 | 68,835 |
| 90 Day Avg. Volume | 9,146 | 73,432 |
| Last Close | ₹31.70 | ₹1,185.10 |
| 52 Week Range | ₹27.33 - ₹52.10 | ₹1,080.00 - ₹1,584.25 |
| % from 52W High | -39.16% | -25.19% |
| All-Time High | ₹134.90 (Sep 10, 2018) | ₹1,584.25 (Nov 04, 2024) |
| % from All-Time High | -76.50% | -25.19% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.15% | 0.28% |
| Quarterly Earnings Growth | -0.41% | 0.38% |
| Financial Health | ||
| Profit Margin (TTM) | 0.01% | 0.02% |
| Operating Margin (TTM) | 0.03% | 0.03% |
| Return on Equity (TTM) | 0.03% | 0.05% |
| Debt to Equity (MRQ) | 121.85 | 21.76 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹16.09 | ₹396.70 |
| Cash per Share (MRQ) | ₹2.77 | ₹73.09 |
| Operating Cash Flow (TTM) | ₹38.31M | ₹-1,784,970,000 |
| Levered Free Cash Flow (TTM) | ₹28.06M | ₹948.20M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Zenlabs Ethica vs Entero Healthcare
| Metric | ZENLABS | ENTERO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 78.02 | 54.82 |
| Forward P/E | N/A | 22.58 |
| PEG Ratio | N/A | N/A |
| Price to Sales (TTM) | 0.42 | 0.96 |
| Price to Book (MRQ) | 1.99 | 3.01 |
| Market Capitalization | ||
| Market Capitalization | ₹214.64M | ₹51.95B |
| Enterprise Value | ₹316.31M | ₹57.20B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.62 | 1.06 |
| Enterprise to EBITDA | 12.31 | 29.36 |
| Risk & Other Metrics | ||
| Beta | -0.77 | N/A |
| Book Value per Share (MRQ) | ₹16.09 | ₹396.70 |
Financial Statements Comparison: Zenlabs Ethica vs Entero Healthcare
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ZENLABS | ENTERO |
|---|---|---|
| Revenue/Sales | ₹129.85M | ₹13.39B |
| Cost of Goods Sold | ₹87.02M | ₹12.08B |
| Gross Profit | ₹42.84M | ₹1.31B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹3.41M | ₹404.21M |
| EBITDA | ₹6.97M | ₹561.07M |
| Pre-Tax Income | ₹1.55M | ₹371.25M |
| Income Tax | ₹644,000 | ₹58.02M |
| Net Income (Profit) | ₹906,000 | ₹314.23M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ZENLABS | ENTERO |
|---|---|---|
| Cash & Equivalents | ₹17.87M | ₹2.29B |
| Total Current Assets | ₹373.48M | ₹20.76B |
| Total Current Liabilities | ₹281.23M | ₹8.45B |
| Long-Term Debt | ₹5.68M | ₹670.18M |
| Total Shareholders Equity | ₹104.25M | ₹17.70B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹22.92M | ₹1.32B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ZENLABS | ENTERO |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ZENLABS | ENTERO |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 1,780 | 68,835 |
| Average Daily Volume (90 Day) | 9,146 | 73,432 |
| Shares Outstanding | 6.51M | 43.51M |
| Float Shares | 2.12M | 13.00M |
| % Held by Insiders | 0.65% | 0.63% |
| % Held by Institutions | 0.00% | 0.23% |
Dividend Analysis & Yield Comparison: Zenlabs Ethica vs Entero Healthcare
| Metric | ZENLABS | ENTERO |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.08 | N/A |
| 3-Year Avg Dividend Yield | 0.57% | N/A |
| 3-Year Total Dividends | ₹0.25 | N/A |
| Ex-Dividend Date | Jul 29, 2022 | N/A |